Summary & Overview
HCPCS J9331: Injection, sirolimus protein-bound particles, 1 mg
HCPCS Level II code J9331 denotes an injectable formulation: sirolimus protein-bound particles, billed per 1 mg unit. This code is used to capture administration and acquisition costs of a specialty immunosuppressant/antiproliferative agent delivered by injection. Nationally, accurate coding for specialty injectables like J9331 affects medical and pharmacy benefit reconciliation, utilization tracking, and payment for high-cost therapies.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, typical sites of service where the drug is administered, and which payer categories are relevant for coverage and billing. The report also outlines benchmarks related to unit-based billing, common modifier usage, and administrative considerations relevant to outpatient infusion and hospital outpatient settings.
This summary provides clinical and coding context for revenue and compliance teams, pharmacy and therapeutics committees, and contract analysts to understand where J9331 fits within specialty drug billing workflows, payer interactions, and site-of-service implications. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9331 describes an injection of sirolimus protein-bound particles, 1 mg. The service represents administration of a specialty injectable formulation of sirolimus supplied in particle-bound form for parenteral use.
Service type: Medication administration / injectable specialty drug
Typical site of service: Infusion center, outpatient clinic, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with a history of metastatic renal cell carcinoma or subependymal giant cell astrocytoma presents to an outpatient oncology infusion center for administration of sirolimus protein-bound particles (J9331). The patient is evaluated by the oncology nurse and prescribing physician for current weight, recent labs (CBC, CMP, lipid panel), vital signs, and concomitant medications. An informed consent and medication reconciliation are completed. Pharmacy compounds or verifies the dose of J9331 per the physician’s order. The drug is administered intravenously per institutional protocol in a monitored infusion chair or ambulatory infusion suite. The clinical workflow includes medication prep and verification, administration by an oncology nurse, observation for infusion reactions, documentation of lot numbers and units administered, and billing the single HCPCS Level II code J9331 with any appropriate modifiers for circumstances such as services furnished in a hospital outpatient department, discontinued administration, or drug wastage. Typical site of service is an outpatient infusion center, hospital outpatient department, or ambulatory surgical center depending on payer rules and facility capabilities. Follow-up includes post-infusion assessment and scheduling of subsequent doses as ordered by the treating oncologist.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|